2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-163305
    Tyk2-IN-17 3010874-31-1 98%
    Tyk2-IN-17 (compound 185) is a potent TYK2 inhibitor.
    Tyk2-IN-17
  • HY-163335
    MPO-IN-7 98%
    MPO-IN-7 (compound MDC) is a myeloperoxidase inhibitor with the IC50 values of 41 μM, 25 μM and 4.5 μM towards α-Glucosidase, dipeptidyl peptidase-4 and myeloperoxidase, respectively. MPO-IN-7 shows antioxidant and anti-inflammatory activity in vitro.
    MPO-IN-7
  • HY-163336
    14,15-Leukotriene A4 methyl ester 75290-58-3 98%
    14,15-Leukotriene A4 methyl ester (14,15-LTA4 methyl ester) is the methyl esterified form of Leukotriene A4, which can be used for the study of biological effects of leukotrienes.
    14,15-Leukotriene A4 methyl ester
  • HY-163355
    COX-2/15-LOX-IN-5 443790-30-5 98%
    COX-2/15-LOX-IN-5 (Compound 4f) is a dual inhibitor of COX-2/15-LOX. COX-2/15-LOX-IN-5 attenuates increased NF-κB activation in RAW 264.7 macrophages mediated by lipopolysaccharide (HY-D1056). COX-2/15-LOX-IN-5 has anti-inflammatory and antioxidant activities.
    COX-2/15-LOX-IN-5
  • HY-163368
    HDAC6-IN-34 1432508-73-0 98%
    HDAC6-IN-34 (compound 21) is an oral active and selective HDAC6 inhibitor with the IC50 of 18 nM. HDAC6-IN-34 increases the acetylation level of tubulin without affecting histone acetylation in cutaneous T-cell lymphoma cells and inhibits TNF-α secretion in LPS (HY-D1056)-stimulated macrophage cells. HDAC6-IN-34 shows excellent anti-arthritic efficacy in rat.
    HDAC6-IN-34
  • HY-163378
    C5aR1 antagonist 1 2365325-67-1 98%
    C5aR1 antagonist 1 (Compound 7e) is an orally active C5a receptor 1 (C5aR1) antagonist. C5aR1 antagonist 1 is active in DISCO and migration assays, with IC50 values of 38 nM and 17 nM, respectively. C5aR1 antagonist 1 can be used for the research of acute and chronic inflammatory diseases.
    C5aR1 antagonist 1
  • HY-163379
    C5aR1 antagonist 2 2365161-92-6 98%
    C5aR1 antagonist 2 (Compound 6a) is an orally active C5a receptor 1 (C5aR1) antagonist that shows efficacy in inhibiting the C5a-induced neutrophil count increase. C5aR1 antagonist 2 is potent in the DISCO and migration assays, with IC50 values of 21 and 3 nM, respectively. C5aR1 antagonist 2 can be used for the research of acute and chronic inflammatory diseases.
    C5aR1 antagonist 2
  • HY-163390
    RIP1 kinase inhibitor 9 3040025-57-5 98%
    RIP1 kinase inhibitor 9 (compound SY-1) is a selective RIP kinase inhibitor. RIP1 kinase inhibitor 9 effectively suppresses the central inflammatory response induced by epilepsy. RIP1 kinase inhibitor 9 inhibits Z-VAD-FMK (HY-16658B)-induced necroptosis in HT-29 cells with an EC50 of 7.04 nM.
    RIP1 kinase inhibitor 9
  • HY-163394
    CB2 receptor agonist 6 98%
    CB2 receptor agonist 6 (compound 70) is an agonist of CB2R, with EC50 of 162 nM. The IC50 values of CB2 receptor agonist 6 are 4.83 μM for CB1R and 0.88 μM for CB2R. CB2 receptor agonist 6 is a neuroprotective agent that can be used for the reseach of neurological disease.
    CB2 receptor agonist 6
  • HY-163404
    Urease-IN-13 3034860-91-5 98%
    Urease-IN-13 (compound d8) is an inhibitor of urease with an IC50 value of 1.21 μM. Urease-IN-13 can be used in the study of infectious gastritis and gastric ulcer.
    Urease-IN-13
  • HY-163411
    Neutrophil elastase inhibitor 6 98%
    Neutrophil elastase inhibitor 6 is a dual inhibitor of human neutrophil elastase (HNE) and proteinase 3 (PR3), with high selectivity for cathepsin G. Neutrophil elastase inhibitor 6 can be used in the research of chronic neutrophilic inflammatory diseases.
    Neutrophil elastase inhibitor 6
  • HY-163412
    IKKβ-IN-3 98%
    IKKβ-IN-3 (Compound hit4) is a IKKβ inhibitor with an IC50 value of 30.4 nM. IKKβ is a key enzyme in the NF-κB signaling pathway and is involved in the development of many diseases. IKKβ-IN-3 can be used in the study of CAF-induced arthritis.
    IKKβ-IN-3
  • HY-163413
    BRD4-BD1-IN-3 98%
    BRD4-BD1-IN-3 (Compound 4g) is a BRD4-BD1 inhibitor. BRD4-BD1-IN-3 can be used for research of inflammatory disease.
    BRD4-BD1-IN-3
  • HY-163429
    J-1149 2883580-95-6 98%
    J-1149 is a potent ALK5 inhibitor, with an IC50 value of 0.017 μM. J-1149 also shows weak p38α MAP kinase inhibitory activity, with an IC50 value of 0.435 μM. J-1149 can be used for liver fibrosis research.
    J-1149
  • HY-163431
    URAT1 inhibitor 10 3012586-38-5 98%
    URAT1 inhibitor 10 (Compound 23a) is a URAT1 inhibitor. URAT1 inhibitor 10 has oral efficacy and low cytotoxicity. URAT1 inhibitor 10 has high selectivity for OAT1 .
    URAT1 inhibitor 10
  • HY-163458
    Anti-inflammatory agent 77 98%
    Anti-inflammatory agent 77 (C12) is a β-cycloacinamide derived mono-carbonyl curcumin analog and an inhibitor of interleukin-6 (IL-6). Anti-inflammatory agent 77 can be used in the study of wound healing.
    Anti-inflammatory agent 77
  • HY-163466
    FXR agonist 7 3036752-72-1 98%
    FXR agonist 7 (compound 33) is a potent agonist of FXR, with EC50 of 0.1 nM. FXR agonist 7 shows high intestinal distribution, good anti-inflammatory activity.
    FXR agonist 7
  • HY-163478
    TNIK-IN-9 3038178-73-0 98%
    TNIK-IN-9 (Compound 54) is a selective and potent NIK inhibitor, with an IC50 of 1.27 nM. TNIK-IN-9 can inhibit pro-inflammatory cytokines and nitric oxide production. TNIK-IN-9 exhibits significant anti-inflammatory effects, improved mortality, and hepatoprotective effects in sepsis models.
    TNIK-IN-9
  • HY-163493
    NLRP3-IN-35 3033731-64-2 98%
    NLRP3-IN-35 (compound 11) is an NLRP3 inhibitor (IC50 < 1 μM).
    NLRP3-IN-35
  • HY-163494
    NLRP3-IN-36 3033732-58-7 98%
    NLRP3-IN-36 (Compound 111) is an NLRP3 inhibitor (IC50 <1 μM).
    NLRP3-IN-36
Cat. No. Product Name / Synonyms Application Reactivity